Abstract
Identifying areas with high COVID-19 burden and their characteristics can help improve vaccine distribution and uptake, reduce burdens on health care systems, and allow for better allocation of public health intervention resources. Synthesizing data from various government and nonprofit institutions of 3,142 United States (US) counties as of 12/21/2020, we studied county-level characteristics that are associated with cumulative case and death rates using regression analyses. Our results showed counties that are more rural, counties with more White/non-White segregation, and counties with higher percentages of people of color, in poverty, with no high school diploma, and with medical comorbidities such as diabetes and hypertension are associated with higher cumulative COVID-19 case and death rates. We identify the hardest hit counties in US using model-estimated case and death rates, which provide more reliable estimates of cumulative COVID-19 burdens than those using raw observed county-specific rates. Identification of counties with high disease burdens and understanding the characteristics of these counties can help inform policies to improve vaccine distribution, deployment and uptake, prevent overwhelming health care systems, and enhance testing access, personal protection equipment access, and other resource allocation efforts, all of which can help save more lives for vulnerable communities.
Significance statement We found counties that are more rural, counties with more White/non-White segregation, and counties with higher percentages of people of color, in poverty, with no high school diploma, and with medical comorbidities such as diabetes and hypertension are associated with higher cumulative COVID-19 case and death rates. We also identified individual counties with high cumulative COVID-19 burden. Identification of counties with high disease burdens and understanding the characteristics of these counties can help inform policies to improve vaccine distribution, deployment and uptake, prevent overwhelming health care systems, and enhance testing access, personal protection equipment access, and other resource allocation efforts, all of which can help save more lives for vulnerable communities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Resource support was provided by the Cannon cluster supported by the FAS Division of Science, Research Computing Group at Harvard University. This work was funded by NIH grant T32-CA933739 (DL), HD092580 (JTC and BAC), and R35-CA203654-04 (XL).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We registered to join the COVID-19 Data Consortium and access SafeGraph COVID-19 response data on 5/12/2020 by signing the SafeGraph Coronavirus Non-Commercial Data License Agreement (license version dated 4/17/2020). We did not receive a unique registration ID or approval code associated with our registration. The SafeGraph Coronavirus Non-Commercial Data License Agreement stipulates that SafeGraph data cannot be distributed for purposes other than those SafeGraph must be credited as the originator of SafeGraph data in publications or other content that use SafeGraph data. SafeGraph is a private company. SafeGraph COVID-19 data is derived from anonymous cellular location data, which are not associated with individual names or email addesses. The data are aggregated across devices within geographic units. The registration process is free-of-charge for all. All other data are publicly available online without registration.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Paper has been reformatted to focus on identifying counties with high cumulative COVID-19 burden and their characteristics. No new data sources were used.
Data Availability
All materials and code for analysis are available on https://github.com/lin-lab/COVID-Health-Disparities.
